AzTrials
AzTrials

PaediatricsPhase 1/2NCT04771962

Comparison of the Anaesthetic Gases in Maintainance of General Anaesthesia in Paediatrics

A Phase 1/2 study testing DESFLURANE AND SEVOFLURANE in people with Paediatrics and General Anaesthesia, run by Universiti Sains Malaysia at 1 site in Malaysia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Desflurane and Sevoflurane are one of the modern inhalational anaesthetic agents currently in use in anaesthetic practice. The properties of desflurane that has low blood gas solubility coefficient of 0.47 compared to sevoflurane (0.68) made it more advantageous when used with supraglottic airway in maintaining… Read more about this study

Who is it for?
Ages 3 to 12 yearsHealthy volunteers can take part
Conditions the study is for
Paediatrics, General Anaesthesia
What is being tested?
DESFLURANE AND SEVOFLURANE
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteMalaysia
Study dates
1 Jan 2020to 31 Dec 2021
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 12 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Aged: 3 years to 12 years old.
  • ASA (American Society of Anesthesiologist) I
  • BMI (body mass index) less than 95 centile according to age, sex, height
  • Preoperative assessment shows low risk of aspiration and no features of difficult intubation.
  • No history of difficult intubation or history of admission to ICU for airway complication.
  • Operation duration less or equal 2 hours using AmbuAuraGain.

Who cannot join

  • Parent refusal for study participation to give informed consent.
  • Patients who had an upper respiratory tract infection (URTI) within previous 2 weeks or any respiratory disease ( bronchial asthma, hyperactive airway,sleep apnea, chronic lung disease)
  • Known susceptibility to malignant hyperthermia (MH)
  • History of moderate to severe hepatic dysfunction following anaesthesia with desflurane not otherwise explained.

Trial locations and contacts

1 site in 1 country.

Malaysia1 site
  • University of Science Malaysia Hospital

    Kubang Kerian, Kelantan, 16150

Other trials in Malaysia

About this study

Official title: Comparing the Efficacy Between Desflurane and Sevoflurane in Miantainance of Spontaneous General Anaesthesia Using Ambu Aura Gain in Paediatrics Patients

Desflurane and Sevoflurane are one of the modern inhalational anaesthetic agents currently in use in anaesthetic practice. The properties of desflurane that has low blood gas solubility coefficient of 0.47 compared to sevoflurane (0.68) made it more advantageous when used with supraglottic airway in maintaining general anaesthesia in paediatrics . It ensures rapid onset and offset of anaesthesia. Rapid recovery profiles especially among pediatric populations is to ensure less complications associated with prolonged recovery of anaesthesia upon emergence from anaesthesia. Nevertherless, desflurane has its drawback which is it can cause airway irritability related to its pungency. Hence, it is not used as an induction anaesthetic agent in paediatrics. This study was done to evaluate the effectiveness of desflurane in comparison to sevoflurane in maintaining spontaneous general anaesthesia in paediatrics population using Ambu AuraGain .

Read the detailed description

Research design:

  1. Double blinded , randomised controlled trial.
  2. Involving paediatrics patients underwent elective surgeries requiring general anaesthesia in Hospital Universiti Sains Malaysia, Kubang Kerian.
  3. The duration of the study is 24 months.

METHODOLOGY

  1. After Approval from the Ethics Committee of University Sains Malaysia (USM), verbal and written consent will be taken from the patient's parent(s), 1 day prior of the surgery during pre-operative assessment in ward. All medical information of the patient will be kept confidential.
  2. The study will be conducted to patient age 3 years to 12 years old, with body weight between 10-30kg after excluding patient who has a upper respiratory tract infection or known susceptible to malignant hyperthermia.
  3. Patients who fulfil the inclusion and exclusion criteria during pre-operative assessment will be randomized into two group using computer generated randomization. The number generated will be placed in the envelope and allocation will be done on the day of the study prior to anaesthesia : S group (sevoflurane maintainance anaesthesia) = 40 and D group ( desflurane maintainance anaesthesia ) = 40.
  4. Allocation concealment is being applied in this study to prevent selection bias by concealing the allocation sequence until the moment of assessing.
  5. Participants and the researcher( whom assessing the outcomes ) are blinded during intervention ( double blinded ), where as the anesthetist in charge ( operator ) is not blinded.
  6. Standard monitoring with non invasive blood pressure , electrocardiography capnography,and peripheral oxygen saturation ( SPO2) will be used.
  7. Induction of anaesthesia with intravenous fentanyl 2mcg per kg, intravenous propofol of 2mg/kg and 3-4vol% of sevoflurane under 100% O2 mask ventilation.
  8. The AmbuAuraGain will be used, with standard insertion technique.
  9. After induction of anaesthesia, inhalation agent will be switch immediately according to group allocation for maintainance of anaesthesia.
  10. Anaesthesia will be maintained using SEVOFLURANE at MAC of 1.2 to 1.5 for the S group and DESFLURANE at MAC 1.2 to 1.5 for the D group with mixture of oxygen/air mixture for both groups.
  11. IV Paracetamol 15mg/kg and IV Fentanyl 0.5mcg/kg will be given as intraoperative analgesia.
  12. Short acting opiod : IV fentanyl 0.5mcg per kg can be given as rescue analgesia.
  13. At the end of surgery (the last suture put), the inhalational agents will be tapered down and discontinued, 100% oxygen with 6l/min was administered. The Ambu®AuraGain™ will be removed in the operating room once the child is fully awake (i.e: regular breathing, good tidal volume of 6-8ml/kg, gag reflex, grimacing and purposeful movements of the extremities).
  14. The child then will be monitored in operating theatre recovery area until the modified Aldrete score reached 8.
  15. Perioperative events in the operating room will be recorded by a blinded investigator. Any adverse events and emergence agitation during recovery will be recorded by a blinded nurse until patient is discharged to ward.
  16. The first outcome of this study will be the intraoperative hemodynamics during maintainance of anaesthesia.
  17. Baseline hemodynamic (blood pressure, heart rate, mean arterial pressure) of the patient during pre-intubation will be taken. After successful intubation, patient haemodynamics will be recorded at 10 minutes interval until 60 minutes and also during pre extubation and post extubation.
  18. Second outcome will be the time of emergence ( the time interval from gas being off to patient awake,i.e: spontaneous eyes opening) , emergence agitation in recovery area, and the respiratory adverse events that occurs during maintainance of anaesthesia and emergence .
  19. The respiratory events which will be recorded are, (ie: breath holding , bronchospasm, coughing, laryngospasm, copious secretions ( which required suctioning), desaturations ( SpO2 < than 90% ).

SAMPLE SIZE ESTIMATION

Objective 1 : hemodynamic changes ( heart rate)

To estimate the sample size for our study we utilized the G.Power sample size calculator software version 3.1 - Anova : repeated measures . Parametres used in the sample size are :

Effect size f : 0.39 ( for heart rate , Akhtam A. Shoukry et al,2016)

  • 0.05 power : 0.80 number of groups: 2 number of measurements: 10 Standard Deviation within each group : 8.97 Mean group 1 : 68.04, mean group 2 : 75.09

Sample size is 32 per group. Estimated sample size with 10% drop out rate : 70

Objective 2 : Emergence time

To estimate the sample size for our study we utilized the PS: Power and Sample Size Calculations software,version 3.0. We applied the independent t-test. Parametres used in the sample size are :

Standard Deviation = 3.9 ( Demirbilek,2004) Mean difference = 3.8 ( expert opinion ) = 0.05 power = 0.80 m = 1 Sample size is 18 per group. Estimated sample size with 10% drop out rate :40

Objective 3 : Coughing on emergence

To estimate the sample size for our study, we utilized the PS: Power and Sample Size Calculations software,version 3.0. We applied the Dichotomous independent , two proportions,uncorrected chi-square test.

Parametres used in the sample size calculations are :

= 0.05, power = 0.80, m = 1, P0 = 0.49 ( proportion of desflurane among patients who did not cough), Paul at al,2010). P1 = 0.8 ( proportion of desflurane among patients who did cough,) expert opinion ).

Sample size is 36 per group.

Estimated sample size with 10% drop out rate : 80

STATISTICAL DATA ANALYSIS

OBJECTIVE 1:

numerical data will be analysed using ANOVA: repeated measures.

OBJECTIVE 2:

Numerical data will be analysed using independent t test.

OBJECTIVE 3:

Categorical data will be analysed using uncorrected chi square test.

Being tested
DESFLURANE AND SEVOFLURANE
Keywords
paediatrics, spontaneous general anaesthesia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DESFLURANE AND SEVOFLURANEDrug

    Also called Suprane and Sevoflurane

    COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS

Study groups in NCT04771962
Study groupRoleWhat they receive
DESFLURANEExperimentaldesflurane group- this group of patients will be induced with sevoflurane and maintained with desflurane during spontaneous general anaesthesia
Receives: Drug: DESFLURANE AND SEVOFLURANE
SEVOFLURANEActive comparatorthe controlled group.patients will be induced and maintained with sevoflurane through out spontaneous general anaesthesia.
Receives: Drug: DESFLURANE AND SEVOFLURANE

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To compare the blood pressure intraoperatively between desflurane and sevoflurane.

    by measuring the blood pressure

    Measured: up to 18 months

  2. To compare the heart rate intraoperatively between desflurane and sevoflurane.

    by measuring the heart rate

    Measured: up to 18 months

  3. To compare the mean arterial pressure intraoperatively between desflurane and sevoflurane.

    by measuring the mean arterial pressure

    Measured: up to 18 months

Secondary outcomes (2)
  1. To compare the emergence time ( interval from gas being off to patient awake).

    to time how many minutes

    Measured: up to 18 months

  2. To compare the respiratory events intraoperative and post operative

    to observe for the signs :breath holding, bronchospasm,coughing, secretions,desaturations

    Measured: up to 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2021
  2. Study start1 Jan 2020
  3. Primary completion15 Dec 2021
  4. Study completion31 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04771962
Sponsor's protocol ID
USM/JEPem/18050248
Status last verified
Sep 2023
First submitted
4 Nov 2020
Last updated
28 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Lerman J, Hammer GB, Verghese S, Ehlers M, Khalil SN, Betts E, Trillo R, Deutsch J; MAPS Investigators Group. Airway responses to desflurane during maintenance of anesthesia and recovery in children with laryngeal mask airways. Paediatr Anaesth. 2010 Jun;20(6):495-505. doi: 10.1111/j.1460-9592.2010.03305.x. Epub 2010 Apr 23.

    PubMed 20456065
  • Akhtam A. Shoukry, Ayman Abd Laltif,Amr Abd Fattah, Ibrahim Abd Ghani, Mohamed Serag. Isoflurane versus desflurane : hemodynamic parametres and recovery charecteristics:a comparative study.Ain Shams Journal of Anaesthesiology 2016,9:45-51

  • Demirbilek S, Togal T, Cicek M, Aslan U, Sizanli E, Ersoy MO. Effects of fentanyl on the incidence of emergence agitation in children receiving desflurane or sevoflurane anaesthesia. Eur J Anaesthesiol. 2004 Jul;21(7):538-42. doi: 10.1017/s0265021504007069.

    PubMed 15318465
  • White PF, Tang J, Wender RH, Yumul R, Stokes OJ, Sloninsky A, Naruse R, Kariger R, Norel E, Mandel S, Webb T, Zaentz A. Desflurane versus sevoflurane for maintenance of outpatient anesthesia: the effect on early versus late recovery and perioperative coughing. Anesth Analg. 2009 Aug;109(2):387-93. doi: 10.1213/ane.0b013e3181adc21a.

    PubMed 19608808
  • Kim EH, Song IK, Lee JH, Kim HS, Kim HC, Yoon SH, Jang YE, Kim JT. Desflurane versus sevoflurane in pediatric anesthesia with a laryngeal mask airway: A randomized controlled trial. Medicine (Baltimore). 2017 Sep;96(35):e7977. doi: 10.1097/MD.0000000000007977.

    PubMed 28858134
  • Sethi S, Ghai B, Ram J, Wig J. Postoperative emergence delirium in pediatric patients undergoing cataract surgery--a comparison of desflurane and sevoflurane. Paediatr Anaesth. 2013 Dec;23(12):1131-7. doi: 10.1111/pan.12260. Epub 2013 Sep 19.

    PubMed 24102666
  • Davis PJ, Cohen IT, McGowan FX Jr, Latta K. Recovery characteristics of desflurane versus halothane for maintenance of anesthesia in pediatric ambulatory patients. Anesthesiology. 1994 Feb;80(2):298-302. doi: 10.1097/00000542-199402000-00009.

    PubMed 8311312
  • Jindal R, Kumra VP, Narani KK, Sood J. Comparison of maintenance and emergence characteristics after desflurane or sevoflurane in outpatient anaesthesia. Indian J Anaesth. 2011 Jan;55(1):36-42. doi: 10.4103/0019-5049.76604.

    PubMed 21431051
  • Satyanarayana A, Aparanji K, Gopalakrishna K. Comparison of airway responses, haemodynamics and recovery using sevoflurane and desflurane via laryngeal mask airway in day care paediatric surgeries. J. Evid. Based Med. Healthc. 2017; 4(92), 5559-5563.

  • Kotwani MB, Malde AD. Comparison of maintenance, emergence and recovery characteristics of sevoflurane and desflurane in pediatric ambulatory surgery. J Anaesthesiol Clin Pharmacol. 2017 Oct-Dec;33(4):503-508. doi: 10.4103/joacp.JOACP_194_16.

    PubMed 29416244

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing DESFLURANE AND SEVOFLURANE in people with Paediatrics and General Anaesthesia, run by Universiti Sains Malaysia at 1 site in Malaysia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To compare the blood pressure intraoperatively between desflurane and sevoflurane. (time frame: up to 18 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04771962, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in